Regulatory T lymphocytes expressing CD4, high levels of CD25, and the transcription factor Foxp3 play a crucial role in the control of immune responses to self and nonself antigens. In contrast to immunosuppressive drugs currently used to treat immunopathology, these cells act in a very specific manner. Consequently, their clinical potential in the treatment of autoimmune disorders, inflammatory diseases, graft-versus-host disease, and allograft rejection is currently extensively studied in experimental animal models as well as in clinical trials. We have previously shown that appropriately in vitro stimulated CD4(+)CD25(high) regulatory T cells can be used to prevent rejection of bone marrow, skin, and heart allografts in the Mouse. We here describe the protocols used in our laboratory to isolate mouse regulatory T cells, to stimulate them in vitro in order to enrich in cells specific for donor-antigens, and to transplant bone marrow under cover of regulatory T cells. Thus, generated hematopoietic chimeras may subsequently be transplanted with solid tissues and organs from the same donor.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/978-1-61737-979-6_12 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!